To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia

Enzychem Lifesciences

Status and phase: Completed; Phase 2

Conditions: COVID-19

Treatments: Drug: Placebo EC-18; Drug: EC-18

Study type: Interventional

Funder types: Industry

Identifiers

NCT04500132

EC-18-C201

Details and patient eligibility

About

Prevention of COVID-19 infection to severe pneumonea or ARDS

Enrollment: 63 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent
• Male or female age 19 years or older
• Pathologically confirmed diagnosis of COVID-19 Infection to Pneumonia

Exclusion criteria

• Pathologically confirmed diagnosis of bacterial pneumonia or viral pneumonia
• Pregnant or nursing at the time of signing informed consent
• Known sensitivity to any study medication
• Unwilling or unable to complete study diary
• Any other condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the protocol

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

63 participants in 2 patient groups, including a placebo group

EC-18 Arm

Experimental group

Description:

EC-18 QD

Treatment:

Drug: EC-18

Placebo Arm

Placebo Comparator group

Description:

Placebo EC-18 QD

Treatment:

Drug: Placebo EC-18